cladribine
NDA- Indications
- Multiple sclerosis
Company intelligence / Profile preview
Hopewell Pharma Ventures focuses on developing and bringing to market complex, limited-competition generic drugs in the United States. The company has filed Abbreviated New Drug Applications (ANDAs) and is engaged in mid-to-late-stage development projects. It has demonstrated expertise in navigating regulatory and intellectual property hurdles, as evidenced by recent legal victories enabling potential entry of generics for important medications such as cladribine for multiple sclerosis[1][2][9]. Specific clinical results are not publicly available.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hopewell Pharma Ventures.